Conditions: Marginal Zone Lymphoma
Keywords: Marginal Zone Lymphoma Non-gastric extranodal Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Nodal Marginal Zone Lymphoma Gastric Marginal Zone Lymphoma MZL Non-gastric extranodal MZL Splenic MZL Nodal MZL Gastric MZL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).

Detailed description:
This phase II study will assess the clinical response rate to Ibritumomab Tiuxetan in patients with untreated nodal, splenic and non-gastric extranodal MZL as well as in antibiotic resistant patients with mucosa-associated lymphoid tissue (MALT) gastric lymphoma.

Arms:
arm 1: Ibritumomab Tiuxetan (Zevalin) + Rituximab

Interventions: intervention 1: Rituximab intervention 2: Ibritumomab Tiuxetan
Intervention descriptions: intervention 1: IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³ intervention 2: IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:

0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³

Protocol document: